

ISLHD CARDIOVASCULAR CLINICAL TRIALS

Illawarra Heart Health Centre
June 2024

ISLHD CARDIOVASCULAR CLINICAL TRIALS UNIT

**Illawarra Heart
Health Centre**

**Wollongong Hospital
Loftus Street
Wollongong NSW 2500**

Ph 02 4253 4908

Fax 02 4253 4950

**Email
ISLHD-
cardiacresearch@health.nsw.
gov.au**

The Illawarra Shoalhaven Local Health District (ISLHD) Cardiovascular Clinical Trials Unit is situated at the Illawarra Heart Health Centre in Wollongong Hospital. It boasts a specialised team comprising doctors, nurses, and allied health professionals.

This unit actively supports a range of clinical trials, contributing to evidence-based practices, fostering knowledge development and enhancing patient care within the local community.

The clinical trials unit continues to perform at a high standard, consistently achieving recruitment goals across various studies and being amongst the top recruiting sites in Australia.



PREVAIL study 3rd/15 sites
ZEUS study 4th/19 sites
EASY-AS 4th/18 sites
RELEVANT 4th/9 sites



REFERRAL OR CONSULTATION



To discuss your patient with an ISLHD Trials Clinician
please phone the Illawarra Heart Health Centre on 02 4253 4908

ISLHD Cardiovascular Clinical Trials






CURRENTLY OPEN FOR RECRUITMENT

Scan the QR Code for more information including eligibility criteria


Medication trials

Heart Failure & Inflammation	ATHENA: Ziltivekimab (anti-inflammatory monoclonal antibody) versus placebo in patients with heart failure, mildly reduced ejection fraction HFmrEF, or preserved ejection fraction HFpEF. Evaluating functional capacity, heart failure symptoms and systemic inflammation. 4 x Monthly injection	A/Prof Lee	
Acute Myocardial Infarct	ARTEMIS: Ziltivekimab (anti-inflammatory monoclonal antibody) versus placebo on patients with acute myocardial infarct CV outcome study. Monthly injections	A/Prof Lee	

Intervention trials

Aortic stenosis	EASY-AS: A trial of early valve replacement in severe asymptomatic aortic stenosis	Dr Danson	
Hyperlipidaemia	GOAL ASIA: Guideline Oriented Approach to Lipid Lowering In Asia-Pacific	A/Prof Lee	
LV thrombus	RELEVANT: Resolution of left ventricular thrombus with different anti coagulation strategies	Dr Moragues	
Implant device	PROTECT ICD: Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias following Acute Myocardial Infarction	A/Prof Lee	
Pacemakers	PARTICIPATE: Partnering remote monitoring of implanted cardiac devices with intelligent patient engagement	A/Prof Lee	

Observational trials

Heart Failure & Cardiovascular Disease	POSEISON: Observational study looking at prevalence of systemic inflammation in patients with Atherosclerotic Cardiovascular disease and Heart Failure	A/Prof Lee	
---	---	------------	---

Stephen Mackay — Trial Coordinator 02 4253 4624
Martin Walker — Research Nurse 02 4253 4650
Dr Astin Lee — Director of Cardiology Astin.LEE@health.nsw.gov.au

For further information regarding these trials at the Illawarra Heart Health Centre you may also contact the trial coordinators as listed or email ISLHD-cardiacresearch@health.nsw.gov.au